Raymond James initiated coverage of Achieve Life Sciences with a Strong Buy rating and $20 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHV:
- Achieve Life Sciences Announces Leadership Shake-Up and Board Reshuffle
- Achieve Life Sciences CEO John Bencich to leave role, Richard Stewart to succeed
- Achieve Life Sciences reports Q2 EPS (25c), consensus (23c)
- Is ACHV a Buy, Before Earnings?
- Ladenburg bullish on Achieve Life Sciences following BTD for cytisinicline